← Theranostic Atlas Therapy radar Imaging radar All targets Molecules Français Molecules
NeoB Target GRPR Class GRPR antagonist peptide Other names NeoBOMB1
3 ongoing trials
1 radiolabelled forms
0 approved products
60 publications (PubMed)
Structure 3D 2D
Structure from the cited PubChem record (unlabelled ligand, or the labelled form when PubChem only describes that one). Conformer: RDKit (computed conformer, indicative). Rotate with the mouse or a finger.
Properties (PubChem) Molecular formula C77H110N18O18 Molar mass (g/mol) 1,575.8 Exact mass (Da) 1,574.8245 XLogP -4.5 H-bond donors 16 H-bond acceptors 23 Rotatable bonds 44 Heavy atoms 113 InChIKey LDDCOMQLHFUMLP-IGEKPEAISA-N PubChem record CID 73438549 ↗ IUPAC name 2-[4-[2-[[4-[[2-[2-[[(2R)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-(2,6-dimethylheptan-4-ylamino)-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethoxy]acetyl]amino]phenyl]methylamino]-2-oxoethyl]-7,10-bis(carboxymethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetic acid SMILES C[C@@H](C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CC1=CN=CN1)C(=O)NC(CC(C)C)CC(C)C)NC(=O)[C@H](CC2=CNC3=CC=CC=C32)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@@H](CC4=CC=CC=C4)NC(=O)COCC(=O)NC5=CC=C(C=C5)CNC(=O)CN6CCN(CCN(CCN(CC6)CC(=O)O)CC(=O)O)CC(=O)O Radiolabelled forms Form Use Molar mass (labelled form) Ongoing trials Most advanced phase Approval [¹⁷⁷Lu]Lu-NeoB Syntheses and QC ↗ Therapy — 3 Phase 2 —
Atlas trials whose studied drug or title names this vector, with this radionuclide.
Trial Phase Status Sponsor Countries NeoB-Cap1 · [177Lu]NeoB NCT06247995 · Breast Phase 2 Active, not recruiting Novartis Pharmaceuticals 13 [177Lu]NeoB NCT05739942 · Brain (glioma, medulloblastoma…) Phase 1 Active, not recruiting Novartis Pharmaceuticals 6 [177Lu]NeoB NCT05870579 · Breast Phase 1 Active, not recruiting Novartis Pharmaceuticals 7
Other trials listing it among the interventions (comparator, associated scan) · 1 60 publications in PubMed for the query below; the most recent:
NeoB[tiab] OR NeoBOMB1[tiab]
Targeted radionuclide-drug conjugates: Current status and perspectives Eur J Med Chem, 2026 Identification of neoechinulin B metabolites in vivo by UPLC Q/TOF MS and exploration of its anti HCV mechanism based on network pharmacology and molecular docking J Pharm Biomed Anal, 2026 Design, Synthesis, and Preclinical Evaluation of Novel Dimeric RM2-Based Radioligands for GRPR-Targeted Breast Cancer Imaging Mol Pharm, 2026 Aminoglycoside antibiotics drive RNA phase separation bioRxiv, 2026 Radiolabeled-NeoB: A Dual-Action Diagnostic and Therapeutic Agent Targeting Gastrin-Releasing Peptide Receptors in Cancer Curr Protein Pept Sci, 2026 Synthesis and Evaluation of Novel (68)Ga-Labeled GRPR-Targeted PET Tracers Derived from [d-Phe(6),Pro(14)]Bombesin(6-14) and [d-Phe(6),des-Met(14)]Bombesin(6-14) Sequences Mol Pharm, 2026 Phase 1 Study of [(177)Lu]Lu-NeoB in Patients with Advanced Solid Tumors Overexpressing Gastrin-Releasing Peptide Receptor: Preliminary Safety and Dosimetry Results J Nucl Med, 2026 In vivo gastrin releasing peptide receptor expression in SDH deficient wild-type gastrointestinal stromal tumours (GIST): potential for theranostic applications EJNMMI Res, 2025 Sources: PubChem and PubMed (NCBI), ClinicalTrials.gov and CTIS registries, approvals recorded by the atlas. PubChem data as of 28 October 2026.
Cite this page NeoB. Theranostic Atlas, LaRadiopharmacie.fr. Data as of 27 October 2026. https://theranosticatlas.com/molecule/neob/ (accessed [date]).
A monitoring tool with no regulatory value: check every item at its source.